Zhang Hongwen said in an interview a few days ago that the first successful COVID-19 vaccine may come out in March next year, but the effect is unknown.
Academician Gao Fu, member of the Chinese People's Political Consultative Conference and director of the China CDC, said that a good vaccine needs one and a half years or two years of research and development, because it needs to meet the three conditions of "safety, effectiveness and controllable quality".
Facing the emergency of this new infectious disease in COVID-19, Gao Fu thinks that the safety of the vaccine is acceptable at present, and it is expected that the vaccine will be used for some special people before the end of the year.
Sara gilbert, a professor involved in adenovirus vector vaccine research at Jenner Institute, Oxford University, said: "If we get urgent approval from the regulatory authorities and finally verify that the vaccine we developed is effective, then the first batch of one million doses of vaccine can be produced in September."
Zhong Nanshan, an academician of the China Academy of Engineering and head of the senior expert group of the National Health and Wellness Committee, also said in response to a media reporter's question a few days ago that "China's vaccine has developed rapidly and will not be much worse than that of the United States. It is said that the United States can use it on people in September, and China is racing. It is estimated that there will be no difference before and after. " .
Extended data:
In the press release issued by The Lancet, Chen Wei pointed out that the development of vaccines in COVID-19 will face unprecedented challenges. Being able to trigger an immune response does not necessarily mean that vaccines can protect people from COVID-19 virus infection. The latest achievement "shows the good prospect of vaccine development in COVID-19, but we still have a long way to go before this vaccine can be used by everyone".
Experts are also cautious about the prospect of adenovirus vector vaccine, pointing out that one of the major challenges it faces is how to overcome "pre-existing immunity", and further clinical trials are needed to verify the effectiveness of the vaccine in preventing COVID-19 infection.
The results of the first phase clinical trial of People's Health Network-China COVID-19 vaccine are encouraging.
Qilu. Eight kinds of COVID-19 vaccines have entered clinical trials in the world, and the vaccine made in Shandong has been successfully developed.